Zobrazeno 1 - 9
of 9
pro vyhledávání: '"Kazuko Sakai"'
Autor:
Hiroaki Kanemura, MD, MPH, PhD, Toshihide Yokoyama, MD, Ryu Nakajima, MD, PhD, Atsushi Nakamura, MD, PhD, Hiroaki Kuroda, MD, PhD, Yoshitaka Kitamura, MD, PhD, Hiroyasu Shoda, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihiro Miyata, MD, PhD, Tatsuro Okamoto, MD, PhD, Kyoichi Okishio, MD, PhD, Masahide Oki, MD, PhD, Yuichi Sakairi, MD, PhD, Toyofumi Fengshi Chen-Yoshikawa, MD, PhD, Tadashi Aoki, MD, Tatsuo Ohira, MD, PhD, Isao Matsumoto, MD, PhD, Kiyonobu Ueno, MD, PhD, Takuro Miyazaki, MD, PhD, Haruhisa Matsuguma, MD, PhD, Hideoki Yokouchi, MD, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Isamu Okamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Masayuki Takeda, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 5, Iss 4, Pp 100658- (2024)
Introduction: Immune checkpoint inhibitors have recently been approved for the treatment of early-stage NSCLC in the perioperative setting on the basis of phase 3 trials. However, the characteristics of such patients who are susceptible to recurrence
Externí odkaz:
https://doaj.org/article/6165423210284cf69a0cf2aac07b491b
Autor:
Junko Tanizaki, MD, PhD, Hiroaki Kuroda, MD, PhD, Toshihide Yokoyama, MD, Makoto Takahama, MD, PhD, Hiroyasu Shoda, MD, PhD, Atsushi Nakamura, MD, PhD, Yoshitaka Kitamura, MD, PhD, Nobuaki Mamesaya, MD, PhD, Yoshihisa Kadota, MD, PhD, Kenji Sawa, MD, PhD, Kyoichi Okishio, MD, PhD, Morihito Okada, MD, PhD, Chihiro Suminaka, MS, Kenta Noda, PhD, Kazuko Sakai, PhD, Yasutaka Chiba, PhD, Kazuto Nishio, MD, PhD, Kenji Chamoto, PhD, Tasuku Honjo, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 12, Pp 100590- (2023)
Introduction: Perioperative treatment in NSCLC has gained marked attention with the introduction of immune checkpoint inhibitors. Such a paradigm shift has given us additional opportunities to evaluate potential biomarkers in patients with these cura
Externí odkaz:
https://doaj.org/article/3f386ee3f72d427a96a00d99cb19bacc
Autor:
Takamasa Koga, MD, PhD, Junichi Soh, MD, PhD, Akira Hamada, MD, PhD, Yuki Miyano, MS, Toshio Fujino, MD, PhD, Keiko Obata, Shuta Ohara, MD, PhD, Masaya Nishino, MD, PhD, Masato Chiba, MD, PhD, Masaki Shimoji, MD, PhD, Toshiki Takemoto, MD, PhD, Kenichi Suda, MD, PhD, Kazuko Sakai, MD, PhD, Hidenori Sato, PhD, Tetsuya Mitsudomi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 9, Pp 100554- (2023)
Introduction: Lung tumor organoids (LTOs) have attracted attention as in vitro preclinical models; however, their clinical and experimental applications have not been fully established. Methods: We attempted to establish LTOs from resected specimens
Externí odkaz:
https://doaj.org/article/e9026793576d4c6aace4c65a0c8269ab
Autor:
Toshiaki Takakura, MD, Hiroaki Kanemura, MD, MPH, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD, Hidetoshi Hayashi, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 4, Iss 6, Pp 100523- (2023)
Resistance to ROS1 tyrosine kinase inhibitors is inevitable, but it has been unclear whether crizotinib might be effective after the development of entrectinib resistance. We here present a case of ROS1-rearranged NSCLC that responded to crizotinib a
Externí odkaz:
https://doaj.org/article/e7d70624992c46b5bea477f455c8785c
Autor:
Hiroaki Kanemura, MD, MPH, Hidetoshi Hayashi, MD, PhD, Shuta Tomida, PhD, Junko Tanizaki, MD, PhD, Shinichiro Suzuki, MD, PhD, Yusuke Kawanaka, MD, Asuka Tsuya, MD, Yasushi Fukuda, MD, Hiroyasu Kaneda, MD, PhD, Keita Kudo, MD, Takayuki Takahama, MD, PhD, Ryosuke Imai, MD, Koji Haratani, MD, PhD, Yasutaka Chiba, PhD, Tomoyuki Otani, MD, Akihiko Ito, MD, PhD, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 3, Iss 8, Pp 100373- (2022)
Introduction: Despite a considerable benefit of adding immune checkpoint inhibitors (ICIs) to platinum-based chemotherapy for patients with extensive-stage SCLC (ES-SCLC), a durable response to ICIs occurs in only a small minority of such patients. M
Externí odkaz:
https://doaj.org/article/dbb20eead9094769a8713112200e34c2
Autor:
Atsushi Osoegawa, MD, PhD, Masafumi Yamaguchi, MD, PhD, Tomomi Nakamura, MD, PhD, Ryotaro Morinaga, MD, Kentaro Tanaka, MD, PhD, Kosuke Kashiwabara, MD, PhD, Takashi Miura, MD, PhD, Takayuki Suetsugu, MD, PhD, Taishi Harada, MD, PhD, Tatsuma Asoh, MD, PhD, Kenichi Taguchi, MD, PhD, Kazuki Nabeshima, MD, PhD, Junji Kishimoto, MA, Kazuko Sakai, PhD, Kazuto Nishio, MD, PhD, Kenji Sugio, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 7, Pp 100191- (2021)
Introduction: Although treatment with osimertinib confers survival benefits in patients with lung cancer with the EGFR T790M mutation, the mechanism of acquired resistance to osimertinib remains poorly understood. We conducted a prospective observati
Externí odkaz:
https://doaj.org/article/3325e96eb81945d7a9c2b5e282c36d99
Autor:
Kazuto Nishio, MD, PhD, Takashi Seto, MD, Makoto Nishio, MD, PhD, Martin Reck, MD, PhD, Edward B. Garon, MD, MS, Kazuko Sakai, PhD, Koichi Goto, MD, PhD, Terufumi Kato, MD, Yoichi Nakanishi, MD, PhD, Toshiaki Takahashi, MD, PhD, Nobuyuki Yamamoto, MD, PhD, Katsuyuki Kiura, MD, PhD, Yuichiro Ohe, MD, PhD, Tomohide Tamura, MD, Carla Visseren-Grul, MD, Bente Frimodt-Moller, MSc, Rebecca R. Hozak, PhD, Sameera R. Wijayawardana, PhD, Annamaria Zimmermann, MS, Gosuke Homma, PhD, Sotaro Enatsu, MD, PhD, Kazuhiko Nakagawa, MD, PhD
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100171- (2021)
Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic
Externí odkaz:
https://doaj.org/article/3e75f1f8e2034c7bb7923044f4c4d8a7
Autor:
Kazuto, Nishio, Takashi, Seto, Makoto, Nishio, Martin, Reck, Edward B, Garon, Kazuko, Sakai, Koichi, Goto, Terufumi, Kato, Yoichi, Nakanishi, Toshiaki, Takahashi, Nobuyuki, Yamamoto, Katsuyuki, Kiura, Yuichiro, Ohe, Tomohide, Tamura, Carla, Visseren-Grul, Bente, Frimodt-Moller, Rebecca R, Hozak, Sameera R, Wijayawardana, Annamaria, Zimmermann, Gosuke, Homma, Sotaro, Enatsu, Kazuhiko, Nakagawa
Publikováno v:
JTO Clinical and Research Reports
Introduction The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic N
Autor:
Yuichiro Ohe, Toshiaki Takahashi, Yoichi Nakanishi, Kazuko Sakai, Makoto Nishio, Martin Reck, Annamaria Zimmermann, Kazuto Nishio, Carla Visseren-Grul, Edward B. Garon, Takashi Seto, Terufumi Kato, Koichi Goto, Sotaro Enatsu, Bente Frimodt-Moller, Sameera R. Wijayawardana, Katsuyuki Kiura, Gosuke Homma, Nobuyuki Yamamoto, Kazuhiko Nakagawa, Rebecca R. Hozak, Tamura Tomohide
Publikováno v:
JTO Clinical and Research Reports, Vol 2, Iss 6, Pp 100171-(2021)
Introduction: The phase 3 RELAY global study (NCT02411448) revealed significant improvement in progression-free survival (PFS) with ramucirumab plus erlotinib (RAM + ERL) compared with placebo plus ERL (PL + ERL) in untreated EGFR-mutated metastatic